首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Functional and pathological improvements of the hearts in diabetes model by the combined therapy of bFGF-loaded nanoparticles with ultrasound-targeted microbubble destruction
【24h】

Functional and pathological improvements of the hearts in diabetes model by the combined therapy of bFGF-loaded nanoparticles with ultrasound-targeted microbubble destruction

机译:通过bFGF纳米颗粒与超声靶向微泡破坏的联合治疗,可以改善糖尿病模型中心脏的功能和病理

获取原文
获取原文并翻译 | 示例
       

摘要

Diabetic cardiomyopathy (DCM) is the leading cause of morbidity and mortality among the diabetic patients and currently there is no effective means to reverse its pathological progress. Basic fibroblast growth factor (bFGF) has shown promise as a molecular therapy for DCM, but its delivery is inefficient and non-specific. In the present study, a therapy combining nanoparticle (NP) carrier and ultrasound-targeted microbubble destruction (UTMD) was reported the first time for bFGF delivery to the heart of diabetic rats. bFGF-loaded NP (bFGF-NP) were preparedwith Poloxamer 188-grafted heparin copolymer usingwater-in-water technique, and the morphology, encapsulation efficiency, and bioactivity of bFGF-NP were studied. The cellular uptake and cytotoxicity of bFGF-NP were evaluated with primary cultures of the left ventricular (LV) cardiomyocytes in vitro. Therapeutic effects of bFGF-NP/UTMD on the heart of DCM rats were studied by measuring LV systolic and diastolic functions, hemodynamic characteristics and indicators of cardiac remodeling including myocardial collagen volume fraction and capillary density. Results demonstrated that bFGF-NP showed good roundmorphology, efficient bFGF encapsulation and stable bioactivity of bFGF in vitro. bFGF-NP/UTMD combined treatment significantly enhanced the efficiency of bFGF cellular uptake (P<0.05) without obvious cytotoxicity. Significant improvements (P b 0.05) in both cardiac functions and tissue morphology in the DCM rats were observed in bFGF-NP/UTMD group. These were not achievable using free bFGF, bFGF-NP or UTMD treatment alone. Our results show that combining a non-viral vector with UTMD technique is an effective strategy to deliver bFGF to the heart, and the resulting growth factor therapy has demonstrated potential to reverse the progress of DCM by restoring the cardiac functions and even the structure of damaged cardiac tissues.
机译:糖尿病性心肌病(DCM)是糖尿病患者发病和死亡的主要原因,目前尚无有效的方法可逆转其病理进展。碱性成纤维细胞生长因子(bFGF)已显示出可用于DCM的分子疗法的前景,但其递送效率低下且非特异性。在本研究中,首次报道了将纳米粒子(NP)载体与超声靶向微泡破坏(UTMD)结合的疗法,首次将bFGF递送至糖尿病大鼠的心脏。采用水包水技术,采用泊洛沙姆188接枝的肝素共聚物制备了bFGF负载的NP(bFGF-NP),并研究了bFGF-NP的形态,包封效率和生物活性。使用体外培养的左心室(LV)心肌细胞原代培养评估bFGF-NP的细胞摄取和细胞毒性。 bFGF-NP / UTMD对DCM大鼠心脏的治疗作用是通过测量LV的收缩和舒张功能,血液动力学特征以及包括心肌胶原蛋白体积分数和毛细血管密度的心脏重塑指标来进行的。结果表明,bFGF-NP在体外具有良好的圆形性,有效的bFGF包封和稳定的生物活性。 bFGF-NP / UTMD联合治疗可显着提高bFGF细胞摄取效率(P <0.05),且无明显细胞毒性。在bFGF-NP / UTMD组中,DCM大鼠的心脏功能和组织形态均有显着改善(P b 0.05)。仅使用游离bFGF,bFGF-NP或UTMD处理是无法实现的。我们的结果表明,将非病毒载体与UTMD技术相结合是将bFGF递送至心脏的有效策略,并且所产生的生长因子疗法已显示出通过恢复心脏功能甚至受损结构来逆转DCM进程的潜力。心脏组织。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号